Legal and Ethical Analysis of Court-Ordered Ivermectin Treatment for COVID-19
What are the implications of a court requiring a doctor to administer a drug they do not believe is medically indicated?
Pharmaceuticals
-
Read more: Legal and Ethical Analysis of Court-Ordered Ivermectin Treatment for COVID-19 -
Read more: How Social Movements Have Facilitated Access to Abortion During the Pandemic How Social Movements Have Facilitated Access to Abortion During the Pandemic
Further on-the-ground innovations, outside the courtroom and across state borders, will be needed to meet future challenges to abortion access.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Topics range from issues related to FDA’s approval of aducanumab, to an analysis of the communication of survival data in cancer drug labels.
-
Read more: Access-to-Medicines Activists Demand Health Justice During COVID-19 Pandemic Access-to-Medicines Activists Demand Health Justice During COVID-19 Pandemic
Activists in the access-to-medicines movement have mobilized to combat the threat of vaccine/therapeutic apartheid during the COVID-19 pandemic.
-
Read more: CeBIL Annual Symposium 2021 – Orphan Drug Innovation: Needs and Priorities CeBIL Annual Symposium 2021 – Orphan Drug Innovation: Needs and Priorities
What are the most pressing priorities for developing new drugs for rare diseases, and how can legal research help meet these needs?
-
Read more: To Address the Overdose Epidemic, Tackle Pharma Industry Influence To Address the Overdose Epidemic, Tackle Pharma Industry Influence
To combat the opioid epidemic, we have to understand how regulators failed to protect the public health as the market for prescription opioids grew.
-
Read more: COVID-19 and the New Reproductive Justice Movement COVID-19 and the New Reproductive Justice Movement
The pandemic finally shifted the reproductive justice movement’s focus to abortion access, rather than abortion rights.
-
Read more: Why Do Differences in Clinical Trial Design Make It Hard to Compare COVID-19 Vaccines? Why Do Differences in Clinical Trial Design Make It Hard to Compare COVID-19 Vaccines?
Because of differences in how they were tested in clinical trials, it is difficult to make apples-to-apples comparisons for COVID-19 vaccines.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from the month of June 2021.
-
Read more: The Prospects for an IP Waiver Under the TRIPS Agreement The Prospects for an IP Waiver Under the TRIPS Agreement
Going forward, practical solutions should focus on scaling up manufacturing and supply, and improving access and affordability.
